CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for Semaglutide Long-acting Injection from the U.S. Food and Drug Administration (FDA), according to a Monday Hong Kong bourse filing.
The indication for the approval is weight management in adults who are overweight or obese alongside a reduced-calorie diet and increased physical activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments